Association Between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight

J Pediatr. 2018 Aug;199:231-236. doi: 10.1016/j.jpeds.2018.03.067. Epub 2018 May 8.

Abstract

Objective: To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW).

Study design: Using the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal week from 2011 to 2015. We defined PDA as any medical (ibuprofen or indomethacin) or surgical PDA therapy. We collected data up to the day of PDA treatment or postnatal day 18 for infants not diagnosed with PDA. We performed multivariable logistic regression to evaluate the association between PDA and exposure to furosemide.

Results: We included 43 576 infants from 337 neonatal intensive care units, of whom 6675 (15%) underwent PDA treatment. Infants with PDA were more premature and more often exposed to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06).

Conclusions: Furosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy and safety of furosemide in premature infants.

Keywords: furosemide exposure; patent ductus arteriosus; very low birth weight infants.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Ductus Arteriosus, Patent / chemically induced*
  • Ductus Arteriosus, Patent / therapy
  • Female
  • Furosemide / adverse effects*
  • Hospitalization
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / chemically induced*
  • Infant, Premature, Diseases / therapy
  • Infant, Very Low Birth Weight*
  • Logistic Models
  • Male
  • Retrospective Studies
  • Risk Factors
  • Sodium Potassium Chloride Symporter Inhibitors / adverse effects*

Substances

  • Sodium Potassium Chloride Symporter Inhibitors
  • Furosemide